Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo

Abstract

The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.

What is claimed is: 
     
       1. A method for treating an individual with high grade glioma, comprising administering an agent that neutralizes CD95 activity to an individual with high grade glioma, wherein said agent is a CD95 ligand (CD95L) inhibitor comprising
 a fusion protein comprising the extracellular domain of CD95 and a human Fc domain. 
 
     
     
       2. The method of  claim 1 , wherein the fusion protein is a fusion protein of the extracellular domain of the human CD95 with human IgG1-Fc (APG101). 
     
     
       3. The method of  claim 1 , wherein the high grade glioma is a WHO Grade III or IV glioma. 
     
     
       4. The method of  claim 1 , wherein the high grade glioma is a WHO Grade IV glioma. 
     
     
       5. The method of  claim 1 , wherein an interaction between CD95 and the protein p85 of PI3K is inhibited. 
     
     
       6. The method according to of  claim 1 , wherein said agent is administered in an amount sufficient to reduce glial cell migration and/or invasion.